Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MARS2 | Q96GW9 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | UGCG | Q16739 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112603 | 1.00 | GPR88 (0.49) | GPR88LMNATSHRCNR2NPSR1 | |
| SCHEMBL28217023 | 0.85 | GPR88 (0.44) | GPR88LMNATSHRCNR2NPSR1 | |
| SCHEMBL836812 | 0.84 | NPSR1 (0.48) | GPR88LMNACNR2NPSR1NPY5R | |
| SCHEMBL12406505 | 0.81 | ATM (0.60) | GPR88TSHRCNR2ALDH1A1CYP3A4 | |
| SCHEMBL31037745 | 0.80 | LMNA (0.47) | LMNATSHRALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL15674956 | 0.80 | GPR88 (0.50) | GPR88CNR2NPSR1ALDH1A1AOC3 | |
| SCHEMBL3103924 | 0.80 | UGCG (0.66) | LMNAALDH1A1SMN1; SMN2UGCGKDM4E | |
| SCHEMBL3636099 | 0.80 | UGCG (0.66) | LMNAALDH1A1SMN1; SMN2UGCGKDM4E | |
| SCHEMBL3103915 | 0.80 | UGCG (0.66) | LMNAALDH1A1SMN1; SMN2UGCGKDM4E | |
| SCHEMBL23100736 | 0.80 | GPR88 (0.68) | GPR88CNR2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10220039-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | GENZYME CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-9744153-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160338996-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2016-11-24 | — | — | US | disclosed |
| US-9481671-B2 | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease | GENZYME CORPORATION (US) | 2016-11-01 | — | — | US | disclosed |
| EP-2594564-B1 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | GENZYME CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9272996-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225393-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2015-08-13 | — | — | US | disclosed |
| US-20150216872-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION | 2015-08-06 | — | — | US | disclosed |
| US-8940776-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140336174-A1 | Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease | GENZYME CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-8729075-B2 | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease | GENZYME CORPORATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130225573-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| US-8389517-B2 | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease | GENZYME CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120322786-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322787-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-12-20 | — | — | US | disclosed |
| US-8309593-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-8304447-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100256216-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216872-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | GPR88 2719/4885LMNA 886/4885TSHR 4238/4885 |
| US-20140336174-A1 | Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease | GBA1, UGCG, GBA2 | GPR88 1228/4885LMNA 568/4885TSHR 3985/4885 |
| US-10220039-B2 | Method of treating polycystic kidney diseases with ceramide derivatives | SGMS1, SGMS2, CERS2 | GPR88 2719/4885LMNA 886/4885TSHR 4238/4885 |
| US-20150225393-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | GPR88 3220/4885LMNA 1311/4885TSHR 2541/4885 |
| US-20100256216-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | ASAH2, GBA1, GAA | GPR88 3220/4885LMNA 1311/4885TSHR 2541/4885 |
| US-20120322786-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | GPR88 1852/4885LMNA 1678/4885TSHR 3687/4885 |
| US-20170258802-A1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | SGMS1, SGMS2, CERS2 | GPR88 2719/4885LMNA 886/4885TSHR 4238/4885 |
| US-20130225573-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GBA1, UGCG, GBA2 | GPR88 1228/4885LMNA 568/4885TSHR 3985/4885 |
| US-20120322787-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | ASAH2, GBA1, GAA | GPR88 3220/4885LMNA 1311/4885TSHR 2541/4885 |
| US-20160338996-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GBA1, GBA2, ASAH2 | GPR88 1852/4885LMNA 1678/4885TSHR 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.